Supplemental Tables and Figures

Table S1. Baseline Characteristics

|  |  |  |
| --- | --- | --- |
| **% unless otherwise indicated** | **TAF n=866** | **TDF n=867** |
| Demographics | | |
| Median age, years (range) | 33 (18, 74) | 35 (18, 76) |
| Female | 15 | 15 |
| Race and ethnicity |  |  |
| Black or African heritage | 26 | 25 |
| Asian | 11 | 10 |
| Hispanic or Latino | 19 | 19 |
| HIV Disease Characteristics | | |
| Median CD4 count, cells/μL | 404 | 406 |
| CD4 <50 cells/μL | 3 | 3 |
| HIV-1 RNA >100,000 c/mL | 23 | 22 |
| Medical History | | |
| Diabetes mellitus | 3 | 5 |
| Hypertension | 14 | 17 |
| Cardiovascular disease | 1 | 2 |
| Hyperlipidemia | 14 | 13 |
| Median estimated GFR, mL/min (Cockcroft-Gault) | 117 | 114 |
| Median BMI (kg/m2) | 24 | 25 |

Table S2. Adverse events leading to discontinuation

|  |  |  |
| --- | --- | --- |
| **n** | **TAF** | **TDF** |
| Renal Adverse Events | | |
| blood creatinine increased + GRF decreased | 0 | 1 |
| decreased GFR | 0 | 1 |
| Fanconi syndrome + glycosuria | 0 | 1 |
| nephropathy | 0 | 1 |
| proteinuria | 0 | 1 |
| renal failure | 0 | 1 |
| renal failure | 0 | 1 |
| renal tubular disorder | 0 | 1 |
| renal tubular disorder | 0 | 1 |
| renal tubular disorder | 0 | 1 |
| creatinine increased + bone density decreased | 0 | 1 |
| bladder spasm\* | 0 | 1 |
| Bone Adverse Events | | |
| bone density decreased | 0 | 1 |
| bone density decreased | 0 | 1 |
| bone loss | 0 | 1 |
| osteopenia | 0 | 1 |
| osteoporosis | 0 | 1 |
| Other Adverse Events | | |
| cardiac arrest | 0 | 1 |
| stroke | 1 | 0 |
| blood triglycerides elevated | 1 | 0 |
| Diffuse large B-cell lymphoma | 1 | 0 |
| dyspnea + hyperkeratosis + abdominal pain + lipodystrophy | 1 | 0 |
| Erectile dysfunction | 1 | 0 |
| eye pain, pruritis, irritation | 1 | 0 |
| Hodgkin's disease | 1 | 0 |
| pharyngitis + product difficult to swallow | 1 | 0 |
| proctalgia, penile pain | 1 | 0 |
| rash | 1 | 0 |
| suicide attempt | 1 | 0 |
| abdominal pain, TMJ, HA, depression | 0 | 1 |
| acne + arthralgia | 0 | 1 |
| drug abuse + mood disorder | 0 | 1 |
| dysphagia + nausea + vomit | 0 | 1 |
| Hodgkin’s disease (+weight loss, loss of appetite, night sweats, dry cough) | 0 | 1 |
| hyperamylasaemia | 0 | 1 |
| iridocyclitis | 0 | 1 |
| IRIS 2/2 HBV | 0 | 1 |
| lung CA | 0 | 1 |
| rash | 0 | 1 |
| spider bite, dermatitis | 0 | 1 |
| **TOTAL** | **11** | **29** |

\*This event is not likely to be associated with proximal renal tubular dysfunction.

Table S3. Joint Status of Combined Renal Laboratory Abnormalities Based on 4 Laboratory Tests With Serum Glucose Cutoff at ≤ 100 mg/dL

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Renal Laboratory Abnormality** | | | **Confirmed ≥0.40 mg/dL increase from BL in SCr** | | | | | |
| **TAF (n=866)** | | | **TDF (n=867)** | | |
| **Proteinuria** | **Normoglycemic Glycosuria** | **Hypophosphatemia** | **Yes (n=11)** | **No (n=855)** | **Total (n=866)** | **Yes (n=34)** | **No (n=833)** | **Total (n=867)** |
| Yes | Yes | Yes | 0 | 0 | 0 | 0 | 0 | 0 |
| Yes | Yes | No | 0 | 0 | 0 | 2 (0.2%) | 0 | 2 (0.2%) |
| Yes | No | Yes | 0 | 0 | 0 | 0 | 0 | 0 |
| Yes | No | No | 0 | 3 (0.3%) | 3 (0.3%) | 2 (0.2%) | 2 (0.2%) | 4 (0.5%) |
| No | Yes | Yes | 0 | 0 | 0 | 0 | 0 | 0 |
| No | Yes | No | 0 | 2 (0.2%) | 2 (0.2%) | 3 (0.3%) | 2 (0.2%) | 5 (0.6%) |
| No | No | Yes | 0 | 4 (0.5%) | 4 (0.5%) | 0 | 10 (1.2%) | 10 (1.2%) |
| No | No | No | 11 (1.3%) | 846 (97.7%) | 857 (99.0%) | 27 (3.1%) | 819 (94.5%) | 846 (97.6%) |
| Total | Total | Total | 11 (1.3%) | 855 (98.7%) | 866 (100.0%) | 34 (3.9%) | 833 (96.1%) | 867 (100.0%) |

Proteinuria is defined as confirmed ≥ 2 grade-level increase from baseline (BL) in graded urine protein; normoglycemic glycosuria is defined as confirmed ≥ 1 grade-level increase from BL in graded urine glucose concurrent with confirmed serum glucose ≤ 100 mg/dL; hypophosphatemia is defined as confirmed ≥ 1 grade-level increase from BL in graded phosphate.

Confirmed laboratory abnormalities are defined as abnormalities observed at 2 consecutive postbaseline measurements within the last dose date plus 30 days or an abnormality observed at 1 postbaseline measurement followed by premature study drug discontinuation

Table S4. Patients Having at Least 2 out of 4 Confirmed Renal Laboratory Abnormalities With Serum Glucose Cutoff at ≤ 100 mg/dL

|  |  |  |  |
| --- | --- | --- | --- |
|  | **TAF (n=866)** | **TDF (n=867)** | **p-value** |
| Meeting 2 out of 4 Confirmed Renal Laboratory Abnormality Criteria | 0 | 7 (0.8%) | 0.015 |

P-value was from the 2-sided Fisher’s exact test to compare the 2 treatment groups.

Figure S1. Forest Plot of Treatment Difference in HIV-1 RNA <50 copies/mL at Week 144 (Snapshot Algorithm) by Subgroup



